EXHIBIT NO. 99.1

     ALTAREX ANNOUNCES RESIGNATION OF CHAIRMAN AND CHIEF SCIENTIFIC OFFICER

WALTHAM, Mass., July 19 /CNW/ -- AltaRex Corp. (TSE: AXO, OTC: ALXFF.PK)
announced today that Dr. Antoine Noujaim has resigned as Chairman, Director, and
Chief Scientific Officer of the Company in order to pursue other opportunities.
The Company expressed its gratitude to Dr. Noujaim for his long service to
AltaRex and wished him well in his new endeavours.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000831/ALTERXLOGO)

Jacques R. Lapointe, the Company's Vice-Chairman, has been appointed Chairman,
effective immediately. The Company does not intend to appoint a Chief Scientific
Officer at this time.

Additional information about AltaRex research and development, clinical trials,
news and events can be found on the Company website www.altarex.com.

This news release contains forward-looking statements that involve risks and
uncertainties, which may cause actual results to differ materially from the
statements made. For this purpose, any statements that are contained herein that
are not statements of historical fact may be deemed to be forward- looking
statements. Without limiting the foregoing, the words "believes," "anticipates,"
"plans," "intends," "expects" and similar expressions are intended to identify
forward-looking statements. Such risks and uncertainties include, but are not
limited to our need for capital; the risk that the Company can not raise funds
on a timely basis on satisfactory terms or at all; the need to obtain and
maintain corporate alliances, such as the alliance with United Therapeutics, and
the risk that the Company cannot establish corporate alliances, such as the
alliance in Northern Europe that the Company is seeking, on a timely basis, on
satisfactory terms, or at all; changing market conditions; uncertainties
regarding the timely and successful completion of clinical trials and patient
enrollment rates, uncertainty of pre-clinical, retrospective, early and interim
clinical trial results, which may not be indicative of results that will be
obtained in ongoing or future clinical trials; whether the Company and/or its
collaborators will file for regulatory approval on a timely basis; uncertainties
as to when, if at all, the FDA or other regulatory authorities will accept or
approve regulatory filings for the Company's products; the need to establish and
scale-up manufacturing processes, uncertainty as to the timely development and
market acceptance of the Company's products; the risk that the claims allowed
under any issued patent owned or licensed by the Company, will not be
sufficiently broad to protect the Company's technology, that any patents issued
to the Company will not be sustained if challenged in court proceedings or
otherwise or that third parties will be able to develop products or processes
that do not infringe valid patents owned or licensed by the Company; and other
risks detailed from time-to-time in the Company's filings with the United States
Securities and Exchange Commission and Canadian securities authorities. The
Company does not assume any obligation to update any forward-looking statement.

THE TORONTO STOCK EXCHANGE HAS NOT APPROVED OR DISAPPROVED OF THE INFORMATION
CONTAINED HEREIN

FOR FURTHER INFORMATION

Trudy Chimko, Human Resources & Corporate Communications of AltaRex Corp.,
+1-781-672-0138, investor@altarex.com